NCT03338959View on ClinicalTrials.gov

Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 28, 2018

Primary Completion Date

June 8, 2023

Study Completion Date

August 4, 2023

Conditions
Soft Tissue SarcomaRecurrent Soft Tissue Sarcoma
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

RADIATION

Radiation Therapy

Undergo radiation therapy

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER

NCT03338959 - Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter